Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization.

Authors: Yao YX; Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.; Ministry of Education, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China.; Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China., Tang C; Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.; Ministry of Education, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China.; Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China., Si FL; Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.; Ministry of Education, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China.; Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China., Lv JC; Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.; Ministry of Education, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China.; Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China., Shi SF; Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.; Ministry of Education, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China.; Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China., Zhou XJ; Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.; Ministry of Education, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China.; Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China., Liu LJ; Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.; Ministry of Education, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China.; Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China., Zhang H; Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.; Ministry of Education, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China.; Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.

Source: Renal failure [Ren Fail] 2025 Dec; Vol. 47 (1), pp. 2478488. Date of Electronic Publication: 2025 Apr 15.

Publication Type: Journal Article; Meta-Analysis

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8701128 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-6049 (Electronic) Linking ISSN: 0886022X NLM ISO Abbreviation: Ren Fail Subsets: MEDLINE

MeSH Terms: Glucagon-Like Peptide-1 Receptor Agonists* , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/genetics , Diabetes Mellitus, Type 2*/complications , Diabetic Nephropathies*/genetics , Diabetic Nephropathies*/prevention & control , Inflammation*/genetics , Kidney Diseases*/genetics , Kidney Diseases*/prevention & control, Humans ; Mendelian Randomization Analysis ; Glucagon-Like Peptide-1 Receptor/genetics ; Risk Assessment

Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study.

Authors: Reitz J; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA., Rosoff DB; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.; NIH Oxford-Cambridge Scholars Program, University of Oxford, Oxford, UK., Perlstein T; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA., Wagner A; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA., Jung J; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA., Wagner J; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA., Reiner BC; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Lohoff FW; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA. falk.lohoff@nih.gov.

Source: Molecular psychiatry [Mol Psychiatry] 2025 Dec; Vol. 30 (12), pp. 6119-6133. Date of Electronic Publication: 2025 Sep 10.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group Specialist Journals Country of Publication: England NLM ID: 9607835 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5578 (Electronic) Linking ISSN: 13594184 NLM ISO Abbreviation: Mol Psychiatry Subsets: MEDLINE

MeSH Terms: Glucagon-Like Peptide-1 Receptor*/genetics , Glucagon-Like Peptide-1 Receptor*/metabolism , Receptors, Gastrointestinal Hormone*/genetics , Receptors, Gastrointestinal Hormone*/metabolism , Receptors, Gastrointestinal Hormone*/agonists , Binge Drinking*/genetics , Binge Drinking*/drug therapy , Binge Drinking*/metabolism, Humans ; Mendelian Randomization Analysis/methods ; Glucagon-Like Peptide-1 Receptor Agonists ; Male ; Phenotype ; Female ; Gastric Inhibitory Polypeptide/metabolism ; Alcohol Drinking/genetics ; Adult ; Glucagon-Like Peptide 1/metabolism ; Alcoholism/genetics ; Polymorphism, Single Nucleotide/genetics ; Middle Aged

Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review.

Authors: Wen J; California Northstate University College of Medicine, 9700 W Taron Dr, Elk Grove, CA, 95757, USA. Electronic address: jdoub2009@berkeley.edu., Nadora D; California Northstate University College of Medicine, 9700 W Taron Dr, Elk Grove, CA, 95757, USA., Truong A; California Northstate University College of Medicine, 9700 W Taron Dr, Elk Grove, CA, 95757, USA., Bernstein E; California Northstate University College of Medicine, 9700 W Taron Dr, Elk Grove, CA, 95757, USA., How-Volkman C; California Northstate University College of Medicine, 9700 W Taron Dr, Elk Grove, CA, 95757, USA., Razick A; University of California, Los Angeles, 405 Hilgard Ave, Los Angeles, CA, 90095, USA., Razick D; California Northstate University College of Medicine, 9700 W Taron Dr, Elk Grove, CA, 95757, USA., Karabala M; California Northstate University College of Medicine, 9700 W Taron Dr, Elk Grove, CA, 95757, USA., Frezza E; California Northstate University College of Medicine, 9700 W Taron Dr, Elk Grove, CA, 95757, USA.

Source: Nutrition, metabolism, and cardiovascular diseases : NMCD [Nutr Metab Cardiovasc Dis] 2025 Dec; Vol. 35 (12), pp. 104213. Date of Electronic Publication: 2025 Jun 28.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9111474 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1590-3729 (Electronic) Linking ISSN: 09394753 NLM ISO Abbreviation: Nutr Metab Cardiovasc Dis Subsets: MEDLINE

MeSH Terms: Glucagon-Like Peptide-1 Receptor Agonists*/pharmacology , Glucagon-Like Peptide-1 Receptor Agonists*/therapeutic use, Glucagon/agonists ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Glucagon-Like Peptide-1 Receptor/chemistry ; Gastric Inhibitory Polypeptide/agonists ; Receptors, Glucagon/agonists ; Humans ; Anti-Obesity Agents/pharmacology ; Anti-Obesity Agents/therapeutic use ; Animals

Epicardial Fat Inflammation and GLP-1/GIP Receptor Analogs: Are we Shifting our Perspective?

Authors: Iacobellis G; Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami, Miller School of Medicine, 1450 NW 10th Ave, Miami, FL, 33136, USA. giacobellis@med.miami.edu.

Source: Current cardiology reports [Curr Cardiol Rep] 2025 Nov 27; Vol. 27 (1), pp. 161. Date of Electronic Publication: 2025 Nov 27.

Publication Type: Journal Article; Review

Journal Info: Publisher: Current Science Country of Publication: United States NLM ID: 100888969 Publication Model: Electronic Cited Medium: Internet ISSN: 1534-3170 (Electronic) Linking ISSN: 15233782 NLM ISO Abbreviation: Curr Cardiol Rep Subsets: MEDLINE

MeSH Terms: Pericardium*/metabolism , Pericardium*/pathology , Inflammation*/metabolism , Glucagon-Like Peptide-1 Receptor*/metabolism , Receptors, Gastrointestinal Hormone*/metabolism , Adipose Tissue*/metabolism , Coronary Artery Disease*/metabolism, Humans ; Gastric Inhibitory Polypeptide/analogs & derivatives ; Glucagon-Like Peptide-1 Receptor Agonists ; Epicardial Adipose Tissue

Effects of glucagon-like peptide 1 receptor signaling in the dorsolateral septum on ethanol operant self-administration and relapse behaviors.

Authors: Xiao Y; School of Psychology, University of New South Wales, UNSW, Sydney, 2052, Australia. Electronic address: xyqmichelle@gmail.com., Yap JA; School of Psychology, University of New South Wales, UNSW, Sydney, 2052, Australia., Ong ZY; School of Psychology, University of New South Wales, UNSW, Sydney, 2052, Australia. Electronic address: zhiyi.ong@unsw.edu.au.

Source: Neuropharmacology [Neuropharmacology] 2025 Nov 15; Vol. 279, pp. 110640. Date of Electronic Publication: 2025 Aug 14.

Publication Type: Journal Article

Journal Info: Publisher: Pergamon Press Country of Publication: England NLM ID: 0236217 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7064 (Electronic) Linking ISSN: 00283908 NLM ISO Abbreviation: Neuropharmacology Subsets: MEDLINE

MeSH Terms: Ethanol*/administration & dosage , Conditioning, Operant*/drug effects , Conditioning, Operant*/physiology , Glucagon-Like Peptide-1 Receptor*/metabolism , Septal Nuclei*/drug effects , Septal Nuclei*/metabolism, Animals ; Male ; Self Administration ; Rats, Long-Evans ; Rats ; Female ; Recurrence ; Exenatide/pharmacology ; Glucagon-Like Peptide-1 Receptor Agonists ; Signal Transduction/drug effects ; Drug-Seeking Behavior/drug effects ; Alcohol Drinking ; Central Nervous System Depressants/administration & dosage

GLP-1/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis.

Authors: Tian R; The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nan Chang 330006, Jiang Xi, China; The Key Laboratory of Hematology of Jiangxi Province, The Department of Hematology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330006, Jiangxi, China., Liu K; The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nan Chang 330006, Jiang Xi, China; The Department of Geriatrics, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330006, Jiangxi, China., Lai H; The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nan Chang 330006, Jiang Xi, China; The Key Laboratory of Hematology of Jiangxi Province, The Department of Hematology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330006, Jiangxi, China., Liao C; The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nan Chang 330006, Jiang Xi, China; The Key Laboratory of Hematology of Jiangxi Province, The Department of Hematology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330006, Jiangxi, China., Li J; The Key Laboratory of Hematology of Jiangxi Province, The Department of Hematology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330006, Jiangxi, China; The Department of Geriatrics, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330006, Jiangxi, China. Electronic address: ndefy03048@ncu.edu.cn., Tu H; The Department of Geriatrics, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330006, Jiangxi, China. Electronic address: ndefy10061@ncu.edu.cn.

Source: International immunopharmacology [Int Immunopharmacol] 2025 Nov 14; Vol. 165, pp. 115443. Date of Electronic Publication: 2025 Aug 30.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE

MeSH Terms: Mitochondria*/drug effects , Mitochondria*/metabolism , Parkinson Disease*/drug therapy , Parkinson Disease*/metabolism , Neuroprotective Agents*/pharmacology , Neuroprotective Agents*/therapeutic use , Glucagon-Like Peptide-1 Receptor Agonists*, Animals ; Mice ; Humans ; Dopaminergic Neurons/drug effects ; Dopaminergic Neurons/metabolism ; Male ; Disease Models, Animal ; Mice, Inbred C57BL ; Mitophagy/drug effects ; Glucagon-Like Peptide-1 Receptor/metabolism ; Glucagon-Like Peptide-1 Receptor/genetics ; Homeostasis/drug effects ; Dynamins/metabolism ; Glucagon-Like Peptide 1/agonists ; Substantia Nigra/drug effects ; Substantia Nigra/metabolism ; Tirzepatide ; Receptors, Gastrointestinal Hormone

Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study.

Authors: Schechter M; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Ein Kerem Medical Center, P.O.B 12000, 9112001, Jerusalem, Israel. meir.schechter@mail.huji.ac.il.; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. meir.schechter@mail.huji.ac.il.; The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Ramat Gan, Israel. meir.schechter@mail.huji.ac.il.; Dina Recanati School of Medicine, Reichman University, Herzliya, Israel. meir.schechter@mail.huji.ac.il., Fishkin A; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Ein Kerem Medical Center, P.O.B 12000, 9112001, Jerusalem, Israel.; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Mosenzon O; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.; Regeneron Pharmaceuticals Inc., New York, NY, USA., Sehtman-Shachar DR; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Ein Kerem Medical Center, P.O.B 12000, 9112001, Jerusalem, Israel.; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Cukierman-Yaffe T; Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Ramat Gan, Israel.; Department of Epidemiology and Preventive Medicine, School of Public Health, Dear Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel., Leibowitz G; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Ein Kerem Medical Center, P.O.B 12000, 9112001, Jerusalem, Israel.; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Aharon-Hananel G; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Ein Kerem Medical Center, P.O.B 12000, 9112001, Jerusalem, Israel.; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2025 Nov 07; Vol. 24 (1), pp. 426. Date of Electronic Publication: 2025 Nov 07.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE

MeSH Terms: Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/diagnosis , Diabetes Mellitus, Type 2*/epidemiology , Diabetes Mellitus, Type 2*/blood , Glucagon-Like Peptide-1 Receptor Agonists* , Neurodegenerative Diseases*/epidemiology , Neurodegenerative Diseases*/diagnosis , Neurodegenerative Diseases*/prevention & control , Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use , Dipeptidyl-Peptidase IV Inhibitors*/adverse effects , Incretins*/therapeutic use , Incretins*/adverse effects , Blood Glucose*/drug effects , Blood Glucose*/metabolism , Hypoglycemic Agents*/therapeutic use , Hypoglycemic Agents*/adverse effects, Humans ; Female ; Male ; Retrospective Studies ; Middle Aged ; Aged ; Risk Factors ; Time Factors ; Treatment Outcome ; Risk Assessment ; Biomarkers/blood ; Electronic Health Records ; Glucagon-Like Peptide-1 Receptor

YN1548: A novel small-molecule agonist of human glucagon-like peptide-1 receptor for the treatment of type 2 diabetes mellitus and obesity.

Authors: Je IG; Research Laboratories, Ildong Pharmaceutical Co., Ltd, Hwaseong-si, Republic of Korea; Yunovia Co., Ltd, Hwaseong-si, Republic of Korea; Graduate School of Biotechnology, Kyung Hee University, Yongin-si, Republic of Korea., Kim TK; Research Laboratories, Ildong Pharmaceutical Co., Ltd, Hwaseong-si, Republic of Korea., Lee HJ; Research Laboratories, Ildong Pharmaceutical Co., Ltd, Hwaseong-si, Republic of Korea., Lee MY; Yunovia Co., Ltd, Hwaseong-si, Republic of Korea., An KM; Yunovia Co., Ltd, Hwaseong-si, Republic of Korea., Park JT; Yunovia Co., Ltd, Hwaseong-si, Republic of Korea., Kim KY; Graduate School of Biotechnology, Kyung Hee University, Yongin-si, Republic of Korea. Electronic address: kiyoung@khu.ac.kr.

Source: European journal of pharmacology [Eur J Pharmacol] 2025 Nov 05; Vol. 1006, pp. 178143. Date of Electronic Publication: 2025 Sep 11.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0712 (Electronic) Linking ISSN: 00142999 NLM ISO Abbreviation: Eur J Pharmacol Subsets: MEDLINE

MeSH Terms: Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/metabolism , Diabetes Mellitus, Type 2*/blood , Glucagon-Like Peptide-1 Receptor Agonists* , Obesity*/drug therapy , Obesity*/metabolism , Hypoglycemic Agents*/pharmacology , Hypoglycemic Agents*/therapeutic use, Animals ; Humans ; CHO Cells ; Cricetulus ; Male ; Glucagon-Like Peptide-1 Receptor/metabolism ; Rats ; Cyclic AMP/metabolism ; Cricetinae ; Blood Glucose/metabolism ; Blood Glucose/drug effects

Unraveling the obesity-asthma link: A new horizon with glucagon-like peptide-1 receptor agonists in a complex intersection of metabolism and airway disease.

Authors: Menzella F; Pulmonology Unit, S. Valentino Hospital, AULSS2 Marca Trevigiana, Italy., Cottini M; Allergy and Pneumology Outpatient Clinic, Italy., Chan R; University of Dundee School of Medicine, UK.

Source: The Journal of international medical research [J Int Med Res] 2025 Nov; Vol. 53 (11), pp. 3000605251392717. Date of Electronic Publication: 2025 Nov 05.

Publication Type: Journal Article; Review

Journal Info: Publisher: Sage Publications Country of Publication: England NLM ID: 0346411 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-2300 (Electronic) Linking ISSN: 03000605 NLM ISO Abbreviation: J Int Med Res Subsets: MEDLINE

MeSH Terms: Asthma*/drug therapy , Asthma*/metabolism , Asthma*/complications , Obesity*/drug therapy , Obesity*/complications , Obesity*/metabolism , Glucagon-Like Peptide-1 Receptor Agonists*, Humans ; Glucagon-Like Peptide-1 Receptor/metabolism ; Animals ; Insulin Resistance ; Metabolic Syndrome/drug therapy ; Metabolic Syndrome/metabolism

Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist.

Authors: Qi W; Translational Sciences and Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Boca SM; Oncology Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Boianelli A; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Fredberg M; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Lundqvist S; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Davies G; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Field J; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Brighton CA; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Snijder A; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Grundevik P; Translational Genomics, Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Eckernäs D; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Träff AM; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Polla M; Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Pettersen D; Projects, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Omar S; Projects, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Hansen L; Translational Sciences and Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Janzén D; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Melin J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., van Zuydam N; Data Sciences & Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Logue J; Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Wallenius K; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Electronic address: kristina.wallenius@astrazeneca.com.

Source: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2025 Oct; Vol. 392 (10), pp. 103683. Date of Electronic Publication: 2025 Aug 28.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE

MeSH Terms: Glucagon-Like Peptide-1 Receptor Agonists* , Hypoglycemic Agents*/administration & dosage , Hypoglycemic Agents*/pharmacokinetics , Hypoglycemic Agents*/pharmacology , Hypoglycemic Agents*/adverse effects, Animals ; Humans ; Male ; Mice ; Administration, Oral ; Female ; Adult ; Macaca fascicularis ; Middle Aged ; Drug Evaluation, Preclinical/methods ; Insulin/metabolism ; Young Adult ; Dose-Response Relationship, Drug ; Glucagon-Like Peptide-1 Receptor/metabolism ; Body Weight/drug effects ; Glucose Tolerance Test

Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide.

Authors: He X; Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, 110022, Liaoning Province, China; Clinical Department I, China Medical University, Shenyang, 110122, Liaoning Province, China. Electronic address: neveah_he@163.com., Zhao Z; First Clinical Medical College, China Medical University, Shenyang, 110122, Liaoning Province, China., Sun Y; Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, 110022, Liaoning Province, China. Electronic address: suny6@sj-hospital.org., Jiang X; Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, 110022, Liaoning Province, China. Electronic address: xijiang1985@126.com.

Source: European journal of medicinal chemistry [Eur J Med Chem] 2025 Dec 15; Vol. 300, pp. 118163. Date of Electronic Publication: 2025 Sep 10.

Publication Type: Journal Article; Review

Journal Info: Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 0420510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1768-3254 (Electronic) Linking ISSN: 02235234 NLM ISO Abbreviation: Eur J Med Chem Subsets: MEDLINE

MeSH Terms: Glucagon-Like Peptides*/adverse effects , Glucagon-Like Peptides*/pharmacology , Glucagon-Like Peptides*/therapeutic use , Glucagon-Like Peptides*/chemistry , Glucagon-Like Peptide-1 Receptor Agonists* , Diabetes Mellitus, Type 2*/drug therapy , Hypoglycemic Agents*/adverse effects , Hypoglycemic Agents*/pharmacology , Hypoglycemic Agents*/chemistry , Hypoglycemic Agents*/therapeutic use, Humans ; Animals ; Glucagon-Like Peptide-1 Receptor/metabolism ; Glucagon-Like Peptide 1

The role of GLP-1 receptor in pain disorders and its pharmacological properties.

Authors: Jing F; The Thirteenth People's Hospital of Chongqing, Chongqing Geriatrics Hospital, Chongqing, 400053, China. Electronic address: jfeng325@163.com., Zeng Y; The Thirteenth People's Hospital of Chongqing, Chongqing Geriatrics Hospital, Chongqing, 400053, China., Yu QL; The Thirteenth People's Hospital of Chongqing, Chongqing Geriatrics Hospital, Chongqing, 400053, China., Fu CJ; The Thirteenth People's Hospital of Chongqing, Chongqing Geriatrics Hospital, Chongqing, 400053, China.

Source: European journal of pharmacology [Eur J Pharmacol] 2025 Dec 05; Vol. 1008, pp. 178345. Date of Electronic Publication: 2025 Nov 07.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0712 (Electronic) Linking ISSN: 00142999 NLM ISO Abbreviation: Eur J Pharmacol Subsets: MEDLINE

MeSH Terms: Glucagon-Like Peptide-1 Receptor*/metabolism , Pain*/drug therapy , Pain*/metabolism , Analgesics*/therapeutic use , Analgesics*/pharmacology, Humans ; Animals ; Glucagon-Like Peptide-1 Receptor Agonists

Mechanisms of Glucagon-Like Peptide 1 Receptor Agonist-Induced Facial Lipodystrophy and a Path Toward Prevention.

Authors: Kruglikov IL; Scientific Department, Wellcomet GmbH, Bruchsal, Germany.

Source: Journal of cosmetic dermatology [J Cosmet Dermatol] 2025 Dec; Vol. 24 (12), pp. e70584.

Publication Type: Journal Article; Review

Journal Info: Publisher: Blackwell Science Country of Publication: England NLM ID: 101130964 Publication Model: Print Cited Medium: Internet ISSN: 1473-2165 (Electronic) Linking ISSN: 14732130 NLM ISO Abbreviation: J Cosmet Dermatol Subsets: MEDLINE

MeSH Terms: Glucagon-Like Peptide-1 Receptor Agonists* , Lipodystrophy*/chemically induced , Lipodystrophy*/prevention & control , Hypoglycemic Agents*/adverse effects, Humans ; Face ; Glucagon-Like Peptide-1 Receptor/metabolism ; Receptor, IGF Type 1/metabolism ; Adipose Tissue/drug effects ; Adipose Tissue/metabolism

Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective.

Authors: Ros-Madrid I; Department of Endocrinology and Nutrition, Virgen de la Arrixaca University Hospital, 30120 Murcia, Spain.; Obesity, Diabetes and Metabolism Research Group, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain., Cano-Mármol R; Department of Endocrinology and Nutrition, Virgen de la Arrixaca University Hospital, 30120 Murcia, Spain.; Obesity, Diabetes and Metabolism Research Group, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain., Ferrer-Gomez M; Department of Endocrinology and Nutrition, Virgen de la Arrixaca University Hospital, 30120 Murcia, Spain.; Obesity, Diabetes and Metabolism Research Group, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain., Ramos-Molina B; Obesity, Diabetes and Metabolism Research Group, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain.

Source: Canadian journal of physiology and pharmacology [Can J Physiol Pharmacol] 2025 Dec 01; Vol. 103 (12), pp. 369-377. Date of Electronic Publication: 2025 Nov 18.

Publication Type: Journal Article; Review

Journal Info: Publisher: Canadian Science Publishing Country of Publication: Canada NLM ID: 0372712 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1205-7541 (Electronic) Linking ISSN: 00084212 NLM ISO Abbreviation: Can J Physiol Pharmacol Subsets: MEDLINE

MeSH Terms: Glucagon-Like Peptide-1 Receptor Agonists* , Anti-Inflammatory Agents*/therapeutic use , Anti-Inflammatory Agents*/pharmacology , Inflammation*/drug therapy , Inflammation*/metabolism, Humans ; Animals ; Glucagon-Like Peptide-1 Receptor/metabolism ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/metabolism ; Incretins/therapeutic use

Design, synthesis, and structure-activity relationship study of novel GLP-1/GIP/GCG triple receptor agonists.

Authors: Zhang J; Shanghai Duomirui Biotechnology Ltd., Shanghai, China; School of Biological Engineering Henan University of Technology, Henan, China., Xu H; Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China., Dong Y; Shanghai Duomirui Biotechnology Ltd., Shanghai, China., Feng J; Shanghai Duomirui Biotechnology Ltd., Shanghai, China; China State Institute of Pharmaceutical Industry, Shanghai, China., Li R; School of Biological Engineering Henan University of Technology, Henan, China. Electronic address: zjh2024@haut.edu.cn.

Source: European journal of medicinal chemistry [Eur J Med Chem] 2025 Nov 15; Vol. 298, pp. 118024. Date of Electronic Publication: 2025 Jul 30.

Publication Type: Journal Article

Journal Info: Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 0420510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1768-3254 (Electronic) Linking ISSN: 02235234 NLM ISO Abbreviation: Eur J Med Chem Subsets: MEDLINE

MeSH Terms: Drug Design* , Glucagon-Like Peptide-1 Receptor Agonists* , Glucagon-Like Peptide 1*/agonists , Receptors, Gastrointestinal Hormone*/agonists , Receptors, Gastrointestinal Hormone*/metabolism , Gastric Inhibitory Polypeptide*/agonists , Receptors, Glucagon*/agonists , Receptors, Glucagon*/metabolism , Hypoglycemic Agents*/pharmacology , Hypoglycemic Agents*/chemical synthesis , Hypoglycemic Agents*/chemistry, Structure-Activity Relationship ; Animals ; Mice ; Humans ; Molecular Structure ; Molecular Docking Simulation ; Dose-Response Relationship, Drug ; Glucagon-Like Peptide-1 Receptor/metabolism ; Male

GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance.

Authors: Ngabea MA; Department of Medicine Maitama District Hospital/ College of Medicine Baze University, Abuja, Nigeria., Dimeji IY; Department of Human Physiology, College of Medicine and Health Sciences, Baze University, Nigeria. Electronic address: yusuff.igbayilola@bazeuniversity.edu.ng.

Source: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2025 Nov 14; Vol. 789, pp. 152822. Date of Electronic Publication: 2025 Oct 16.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 0372516 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2104 (Electronic) Linking ISSN: 0006291X NLM ISO Abbreviation: Biochem Biophys Res Commun Subsets: MEDLINE

MeSH Terms: Insulin Resistance*/immunology , Glucagon-Like Peptide-1 Receptor Agonists* , Inflammation*/drug therapy , Inflammation*/immunology , Inflammation*/metabolism , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/immunology , Diabetes Mellitus, Type 2*/metabolism , Hypoglycemic Agents*/therapeutic use , Hypoglycemic Agents*/pharmacology, Humans ; Animals ; Signal Transduction/drug effects ; Glucagon-Like Peptide-1 Receptor ; Metabolic Syndrome/drug therapy ; Metabolic Syndrome/immunology

Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review.

Authors: Tongta S; Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand., Sungkaworn T; Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, Thailand., Pathomthongtaweechai N; Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, Thailand.

Source: International journal of molecular sciences [Int J Mol Sci] 2025 Nov 13; Vol. 26 (22). Date of Electronic Publication: 2025 Nov 13.

Publication Type: Journal Article; Review

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

MeSH Terms: Binge-Eating Disorder*/drug therapy , Binge-Eating Disorder*/metabolism , Glucagon-Like Peptide-1 Receptor Agonists*, Humans ; Animals ; Glucagon-Like Peptide-1 Receptor/metabolism ; Reward ; Liraglutide/therapeutic use ; Liraglutide/pharmacology ; Glucagon-Like Peptide 1

GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders.

Authors: Guo J; Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida 32610., Hayes MR; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104., Leggio L; NIDA/NIAAA, National Institutes of Health Intramural Research Program, Baltimore, Maryland 21224., Oru E; Diabetes, Obesity and Complications Therapeutic Area, Eli Lilly and Company, Indianapolis, Indiana 46285., Rinaman L; Department of Psychology and Program in Neuroscience, Florida State University, Tallahassee, Florida 32304 lrinaman@psy.fsu.edu.

Source: The Journal of neuroscience : the official journal of the Society for Neuroscience [J Neurosci] 2025 Nov 12; Vol. 45 (46). Date of Electronic Publication: 2025 Nov 12.

Publication Type: Journal Article; Review

Journal Info: Publisher: Society for Neuroscience Country of Publication: United States NLM ID: 8102140 Publication Model: Electronic Cited Medium: Internet ISSN: 1529-2401 (Electronic) Linking ISSN: 02706474 NLM ISO Abbreviation: J Neurosci Subsets: MEDLINE

MeSH Terms: Glucagon-Like Peptide-1 Receptor Agonists* , Substance-Related Disorders*/drug therapy , Substance-Related Disorders*/metabolism , Hyperphagia*/drug therapy , Hyperphagia*/metabolism, Humans ; Animals ; Glucagon-Like Peptide-1 Receptor/metabolism ; Obesity/drug therapy

GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways.

Authors: Lucente D; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy., Bellino S; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy., La Salvia A; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy.

Source: Genes [Genes (Basel)] 2025 Nov 10; Vol. 16 (11). Date of Electronic Publication: 2025 Nov 10.

Publication Type: Journal Article; Review

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101551097 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4425 (Electronic) Linking ISSN: 20734425 NLM ISO Abbreviation: Genes (Basel) Subsets: MEDLINE

MeSH Terms: Glucagon-Like Peptide-1 Receptor Agonists* , Neoplasms*/drug therapy , Neoplasms*/metabolism , Neoplasms*/pathology , Antineoplastic Agents*/therapeutic use , Antineoplastic Agents*/pharmacology, Humans ; Signal Transduction/drug effects ; Animals ; Glucagon-Like Peptide-1 Receptor/metabolism ; Apoptosis/drug effects ; Cell Proliferation/drug effects

Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure.

Authors: Crispino SP; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.; Department of Medicine and Surgery, Fondazione Policlinico Campus Bio-Medico, 00128 Rome, Italy.; Department of Biomedical Engineering, Intelligent Technology Laboratory for Health and Wellbeing, Università Campus Bio-Medico di Roma, 00128 Rome, Italy., Nusca A; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.; Department of Medicine and Surgery, Fondazione Policlinico Campus Bio-Medico, 00128 Rome, Italy., Ferro A; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy., Cricco R; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy., Ciancio M; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.; Department of Medicine and Surgery, Fondazione Policlinico Campus Bio-Medico, 00128 Rome, Italy., Segreti A; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.; Department of Medicine and Surgery, Fondazione Policlinico Campus Bio-Medico, 00128 Rome, Italy.; Department of Movement, Human and Health Sciences, University of Rome 'Foro Italico', 00135 Rome, Italy., Cavallari I; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.; Department of Medicine and Surgery, Fondazione Policlinico Campus Bio-Medico, 00128 Rome, Italy., Sabatino M; Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Potena L; Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Ussia GP; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.; Department of Medicine and Surgery, Fondazione Policlinico Campus Bio-Medico, 00128 Rome, Italy., Grigioni F; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.; Department of Medicine and Surgery, Fondazione Policlinico Campus Bio-Medico, 00128 Rome, Italy.

Source: Biomolecules [Biomolecules] 2025 Nov 10; Vol. 15 (11). Date of Electronic Publication: 2025 Nov 10.

Publication Type: Journal Article; Review

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101596414 Publication Model: Electronic Cited Medium: Internet ISSN: 2218-273X (Electronic) Linking ISSN: 2218273X NLM ISO Abbreviation: Biomolecules Subsets: MEDLINE

MeSH Terms: Heart Failure*/drug therapy , Heart Failure*/physiopathology , Heart Failure*/metabolism , Glucagon-Like Peptide-1 Receptor Agonists* , Stroke Volume*/drug effects, Humans ; Glucagon-Like Peptide-1 Receptor/metabolism ; Ventricular Function, Left/drug effects ; Diabetes Mellitus, Type 2/drug therapy ; Glucagon-Like Peptide 1